Assess the value of your early-stage health technology
Calibrayt determines technology health economic value so you can understand and communicate your Value Story.
Calibrayt is for early-stage
health technology developers.
Calibrayt is a platform to build a model of technology potential value to the payer, analyze to understand key drivers of economic value, and to present the product Value Story.
How it Works
Tell us a little about your technology and a starter model is generated.
Follow intuitive guidance to build a credible and robust model.
Analyze technology value, including "what-if" scenarios to fully understand technology payer economics.
Present your value story using attractive interpretive tools.
Plan technology trials and update your model over time with new data and information.
Calibrayt supports companies along the entire R&D and commercialization journey.
Calibrayt is a platform that paces with product development, to provide ongoing insights into the potential economic value and Adoption Case from the perspective of the intended payer.
Estimate Technology PriceIdentify
Identify technology value-based price range in order to determine commercial potential and viability.
Demonstrate
Demonstrate economic attractiveness of the value proposition and likely payer acceptance on the basis of the potential for the technology to be cost-savings, or to be considered cost-effective.
Determine
Determine the minimum required effectiveness necessary to achieve a desired price that is likely acceptable to the payer.
Inform
Inform key strategic decisions on the basis of commercial potential early in the development cycle, for example the most commercially attractive patient segments (e.g., early or late stage disease).
Understand
Understand key economic value drivers to ensure inclusion of necessary data collection during technology trial in order to build the required evidence base for market access.
Update
Update the model over time as trial and other data becomes available, or as standard of care changes, to prepare evidence for presentation to payers.
Calibrayt enables companies to present
their Value Story
Analyses of models on the Calibrayt platform populate robust interpretive presentations of the potential product Value Story, including the value it can provide in terms of improving health, reducing payer costs, and supporting more cost-effective healthcare resource allocation.
Audiences for the Early-Stage Value Story
Investment community
The likelihood of technology being attractive to the payer, at a commercially viable price, is critical to investment decisions.
Granting agencies
The ability to document and quantify technology impact on patient health and health systems is critical to application success.
Accelerators/Incubators
Entry to competitive support organizations is significantly enhanced with a compelling health economic value proposition indicative of commercial success.
Advisors/Champions
Thought leader prioritization of start-up’s to engage with is significantly improved with evidence of technology potential to eventually be procured as it has a compelling Adoption Case.
Technology Trialist
Evidence of the potential for technology to have positive impact on both health and costs strengthens technology trial opportunity, and models once developed serve as the framework for trial design and evaluation.
Expert support available if and when needed.
A global network of accomplished experts, sourced from The ASSESS Project, is available on the Calibrayt platform to support users with building and interpreting a health economic model.
The ASSESS Project
The ASSESS Project helps organizations achieve their most ambitious goals.
The ASSESS Project is the community and movement that supports Calibrayt to deliver insights and analyses to innovators. It builds on 30 years of research and practice in health technology assessment (HTA) and early economic evaluation.
The project has assembled a global community of those interested in early HTA and value demonstration to support university life sciences spin-outs and start-ups, and radically improve the processes and outcomes achieved by innovators and technology transfer offices, and accelerate breakthrough technology to bedside.
From our blog
Lorem ipsum, dolor sit amet consectetur adipisicing elit. Eaque fugit ratione dicta mollitia. Officiis ad.
Blog post title
Some quick example text to build on the card title and make up the bulk of the card's content.
Another blog post title
This text is a bit longer to illustrate the adaptive height of each card. Some quick example text to build on the card title and make up the bulk of the card's content.
The last blog post title is a little bit longer than the others
Some more quick example text to build on the card title and make up the bulk of the card's content.